KDR and neoplasm: Sunitinib, a receptor tyrosine kinase (RTK) inhibitor, plays a pivotal role in the RCC treatment due to its ability to target various receptors, including vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptors (PDGFR), thereby inhibiting angiogenesis and ultimately tumor growth [4].